Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Blood Pressure in Patients With Migraine Treated With Monoclonal Anti-CGRP (Receptor) Antibodies
Simone de Vries Lentsch, Britt W. H. van der Arend, Antoinette MaassenVanDenBrink, et al.
Neurology (2022) Vol. 99, Iss. 17
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

Blood pressure elevation in erenumab‐treated patients with migraine: A retrospective real‐world experience
Nikita Chhabra, Carolyn Mead‐Harvey, Christopher Dodoo, et al.
Headache The Journal of Head and Face Pain (2024) Vol. 64, Iss. 3, pp. 233-242
Closed Access | Times Cited: 16
Impact of CGRP monoclonal antibody treatment on blood pressure in patients with migraine: A systematic review and potential clinical implications
Britt W. H. van der Arend, Floor C. van Welie, Michael Hecht Olsen, et al.
Cephalalgia (2025) Vol. 45, Iss. 1
Closed Access | Times Cited: 2
Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data
Antun R. Pavelić, Christian Wöber, Franz Riederer, et al.
Cells (2022) Vol. 12, Iss. 1, pp. 143-143
Open Access | Times Cited: 38
Neurological and psychiatric comorbidities of migraine: Concepts and future perspectives
Nadine Pelzer, Irene de Boer, Arn M. J. M. van den Maagdenberg, et al.
Cephalalgia (2023) Vol. 43, Iss. 6
Open Access | Times Cited: 33
Migraine and cardiovascular disease: what cardiologists should know
Deborah N. Kalkman, E. G. M. Couturier, Abdelhak el Bouziani, et al.
European Heart Journal (2023) Vol. 44, Iss. 30, pp. 2815-2828
Open Access | Times Cited: 31
The sense of stopping migraine prophylaxis
Linda Al‐Hassany, Hannah Lyons, Deirdre M. Boucherie, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 30
Targeting the PACAP-38 pathway is an emerging therapeutic strategy for migraine prevention
Lanfranco Pellesi, Messoud Ashina, Paolo Martelletti
Expert Opinion on Emerging Drugs (2024) Vol. 29, Iss. 1, pp. 57-64
Open Access | Times Cited: 10
Methodological considerations in assessing the impact of CGRP monoclonal antibodies on blood pressure: The need for a broader perspective
Davide Mascarella, Valentina Favoni, Giulia Pierangeli, et al.
Cephalalgia (2025) Vol. 45, Iss. 4
Closed Access | Times Cited: 1
Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: a narrative review
Jean Schoenen, Annelies Van Dycke, Jan Versijpt, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 17
Pharmacology of erenumab in human isolated coronary and meningeal arteries: Additional effect of gepants on top of a maximum effect of erenumab
Tessa de Vries, Eloísa Rubio‐Beltrán, Antoon van den Bogaerdt, et al.
British Journal of Pharmacology (2024) Vol. 181, Iss. 12, pp. 1720-1733
Open Access | Times Cited: 6
Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2–4 Prior Preventive Treatments Had Failed
Uwe Reuter, Peter J. Goadsby, Michel D. Ferrari, et al.
Neurology (2024) Vol. 102, Iss. 10
Closed Access | Times Cited: 6
Calcitonin gene relating peptide inhibitors in combination for migraine treatment: A mini-review
Tulsi Shah, Kate Bedrin, Amanda Tinsley
Frontiers in Pain Research (2023) Vol. 4
Open Access | Times Cited: 16
Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review
Nicolas Vandenbussche, Karolina Pisarek, Koen Paemeleire
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 12
Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials
Marcello Silvestro, Ilaria Orologio, Mattia Siciliano, et al.
Expert Opinion on Emerging Drugs (2023) Vol. 28, Iss. 2, pp. 79-96
Closed Access | Times Cited: 11
Stroke etiology and white matter burden in women with and without migraine
Anne E. Wilms, Nelleke van der Weerd, Thijs W. van Harten, et al.
The Journal of Headache and Pain (2025) Vol. 26, Iss. 1
Open Access
Effectiveness and safety of anti-CGRP monoclonal antibodies for migraine in patients over 65 years: a systematic review
Albert Muñoz‐Vendrell, A. López-Bravo, Almudena Layos-Romero, et al.
Pain Management (2025), pp. 1-11
Closed Access
Effect of erenumab versus other migraine preventive medications on cardiovascular and cerebrovascular outcomes: A United States claims database‐based observational cohort study
David W. Dodick, Stewart J. Tepper, Jessica Ailani, et al.
Headache The Journal of Head and Face Pain (2025)
Open Access
Assessing blood pressure changes and hypertension‐related outcomes in patients with migraine treated with erenumab: A systematic review and meta‐analysis
Luana Miyahira Makita, Rafael Kleimmann, Rafael Reis de Oliveira, et al.
Headache The Journal of Head and Face Pain (2025)
Closed Access
Calcitonin gene-related peptide-targeted therapy in migraine: current role and future perspectives
Jan Versijpt, Koen Paemeleire, Uwe Reuter, et al.
The Lancet (2025) Vol. 405, Iss. 10483, pp. 1014-1026
Closed Access
Reply to “Methodological considerations in assessing the impact of CGRP monoclonal antibodies on blood pressure”
Britt W. H. van der Arend, Floor C. van Welie, Jan Versijpt, et al.
Cephalalgia (2025) Vol. 45, Iss. 4
Closed Access
Association between migraine and cerebral white matter hyperintensities in middle‐aged and older individuals: A cross‐sectional study using the UK Biobank cohort
Peng‐Peng Niu, Rui Zhang, Chan Zhang, et al.
Headache The Journal of Head and Face Pain (2025)
Closed Access
Hellenic Headache Society Recommendations for the Use of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide Pathway for the Prevention of Migraine and Cluster Headache—2023 Update
Dimos D. Mitsikostas, A. Alexoudi, Chrysa Arvaniti, et al.
SN Comprehensive Clinical Medicine (2023) Vol. 5, Iss. 1
Open Access | Times Cited: 9
Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials
Paul Rizzoli, Michael J. Marmura, Jennifer Robblee, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 3
Blood pressure monitoring in elderly migraineurs starting an anti-CGRP monoclonal antibody: a real-world prospective study
Davide Mascarella, Giorgia Andrini, Carlo Baraldi, et al.
Neurological Sciences (2024) Vol. 45, Iss. 11, pp. 5365-5373
Open Access | Times Cited: 3
Situational prevention in migraine: are we doing the right thing?
Lanfranco Pellesi, Paolo Martelletti
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top